Linking publication about efalizumab effectiveness with safety concerns.
Robinson
June K
JK
D016907:Adverse Drug Reaction Reporting Systems; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D017512:Lichenoid Eruptions / Q000188:drug therapy; D011642:Publications; D018570:Risk Assessment; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; C472181:efalizumab